These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7046521)

  • 1. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
    Katsumura T; Mishima Y; Kamiya K; Sakaguchi S; Tanabe T; Sakuma A
    Angiology; 1982 Jun; 33(6):357-67. PubMed ID: 7046521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of ticlopidine on peripheral obliterating arteriopathy].
    Stiegler H; Hess H; Mietaschk A; Trampisch HJ; Ingrisch H
    Dtsch Med Wochenschr; 1984 Aug; 109(33):1240-3. PubMed ID: 6381015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
    Mishima Y; Kamiya K; Sakaguchi S; Kusaba A; Sakuma A
    Angiology; 1977 Feb; 28(2):84-94. PubMed ID: 326097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
    Knudsen JB; Kjøller E; Skagen K; Gormsen J
    Thromb Haemost; 1985 Jun; 53(3):332-6. PubMed ID: 3901391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of ticlopidine for ischemic leg ulcers.
    Katsumura T
    Agents Actions Suppl; 1984; 15():167-72. PubMed ID: 6385645
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of ticlopidine on the natural course of retinal vein occlusion.
    Houtsmuller AJ; Vermeulen JA; Klompe M; Zahn KJ; Henkes HE; Baarsma GS; Tijssen J
    Agents Actions Suppl; 1984; 15():219-29. PubMed ID: 6385648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
    Aukland A; Hurlow RA; George AJ; Stuart J
    J Clin Pathol; 1982 Jul; 35(7):740-3. PubMed ID: 7047575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
    Nyberg G; Larsson O; Westberg NG; Aurell M; Jagenburg R; Blohmé G
    Clin Nephrol; 1984 Mar; 21(3):184-7. PubMed ID: 6705280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conservative treatment of inoperable arterial occlusions of the lower extremities with intra-arterial prostaglandin E1.
    Gruss JD; Bartels D; Ohta T; Machado JL; Schlechtweg B
    Br J Surg; 1982 Jun; 69 Suppl():S11-3. PubMed ID: 7044465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
    Gröntoft KC; Mulec H; Gutierrez A; Olander R
    Scand J Urol Nephrol; 1985; 19(1):55-7. PubMed ID: 3895411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Platelet release proteins in plasma in peripheral arterial obliterative disease during ticlopidine administration].
    Klingemann HG; Egbring R
    Dtsch Med Wochenschr; 1982 Sep; 107(37):1388-91. PubMed ID: 7117151
    [No Abstract]   [Full Text] [Related]  

  • 12. [20 patients with chronic ischemia of the legs treated with ticlopidine].
    Velasco A; Olabarría I; Ramila P; Domínguez MJ; Iriarte JA
    Angiologia; 1985; 37(5):236-42. PubMed ID: 4073584
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of ticlopidine of platelet function in men with stable angina pectoris.
    Berglund U; von Schenck H; Wallentin L
    Thromb Haemost; 1985 Dec; 54(4):808-12. PubMed ID: 3911481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
    Davì G; Pinto A; Francavilla G; Paterna S; Campisi D; Strano A
    Thromb Res; 1985 Oct; 40(2):275-81. PubMed ID: 2933846
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon.
    Destors JM; Gauthier E; Lelong S; Boissel JP
    Angiology; 1986 Aug; 37(8):565-9. PubMed ID: 2943195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. Design, organization and general characteristics of patients at entry. The EMATAP Group.
    Blanchard JF; Carreras LO
    Nouv Rev Fr Hematol (1978); 1992; 34(2):149-53. PubMed ID: 1502021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Control of platelet antiaggregation therapy using an electronic aggregometer on whole blood].
    Arpaia MR; Leonardo G; del Guercio R
    Minerva Cardioangiol; 1986 Apr; 34(4):195-8. PubMed ID: 3725023
    [No Abstract]   [Full Text] [Related]  

  • 18. [On the therapeutic activity of hemaseril in treatment of ischemic arteriopathies and phlebopathies].
    Tattoni G; Bigazzi P; Gritta G
    Clin Ter; 1974 Mar; 69(3):225-39. PubMed ID: 4846656
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis.
    Kirstein P; Jogestrand T; Johnsson H; Olsson AG
    Atherosclerosis; 1980 Aug; 36(4):471-80. PubMed ID: 7417366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial.
    Schuler JJ; Flanigan DP; Holcroft JW; Ursprung JJ; Mohrland JS; Pyke J
    J Vasc Surg; 1984 Jan; 1(1):160-70. PubMed ID: 6384558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.